PanGenetics
Utrecht
About PanGenetics
PanGenetics develops monoclonal antibodies for the treatment of immune mediated diseases. PanGenetics is a clinical development company that specializes in taking antibodies from the late research stage through to clinical proof of concept. The company is based in Utrecht, the Netherlands with an office in Cambridge, UK. PanGenetics employs a lean business model with manufacturing and clinical development activities outsourced to specialist providers. Apart from PG110, the other clinical program of PanGenetics is PG102, a CD40 antagonist for treatment of autoimmune diseases which is currently being evaluated in a clinical study in psoriatic arthritis patients
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $52.7M
- Funding stage: M&A
- Last round: Series C (Mar 2008)
- Website: pangenetics.com
- Phone: +31302537911
Industries & Categories
Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/pangenetics-3712387 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.